MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

MLTX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

MoonLake ImmunotherapeuticsNASDAQ: MLTX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $845K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $2.34M.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $845K or moves back toward the trailing-twelve-month quarterly average of $584.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$845K+12.5% QoQ
Last fiscal yearDec 2025
$2.62M— YoY
LTMMar 2026
$2.34M+7090.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
2.62M USD
Year-over-year change
—
4-year CAGR
+379.0%

Cost of Revenue vs competitors

How MLTX compares with its peers on the latest reported figures

  • MLTX's LTM Mar 2026 cost of revenue of $2.34M is the 3rd highest of the 11 companies compared; the peer median is $441.5K.
  • Its year-over-year change of +7090.5% is the highest of 7, against a peer median of -25.4%.
MLTX Competitors Peer median
Cost of Revenue for MLTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M -56.9%-53.2%13.5%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$62.25M —-10.0%—
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$2.34M +7090.5%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.98M -86.0%-44.1%23.7%
ALMSAlumis Inc. Common StockLTM Jun 2026$871K +6.2%+140.9%11.8%
ATTOAttovia Therapeutics, Inc.FY2025$804K +156.9%—59.6%
EQEquillium, Inc.LTM Mar 2026$79K ———
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$76K ——4.0%
ZURAZura Bio LimitedLTM Mar 2026$16K +220.0%——
CNTBConnect Biopharma Holdings LimitedFY2025$0 ——0.0%
ANABAnaptysBio, Inc.LTM Mar 2026-$38.15M -122.7%-69.9%16.4%
Peer median (excluding MLTX) $441.5K-25.4%-44.1%13.5%

Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue4.97K0002.62M
Gross Profit(4.97K)000(2.62M)
Gross Margin—————
Research & Development35.52M42.05M31.8M112.77M202.86M
Selling, General & Admin18.05M23.01M22.32M30.32M41.97M
Operating Expenses53.57M65.06M54.12M143.09M242.22M
Depreciation & Amortization4.97K164.78K370.32K1.38M2.62M
EBITDA(53.63M)(64.3M)(43.61M)(119.58M)(219.85M)
EBITDA Margin—————
Operating Income(53.58M)(65.06M)(54.12M)(143.09M)(244.83M)
Operating Margin—————
Interest Income00000
Interest Expense00007.25M
Other Income / Expenses(61.85K)591.73K10.14M22.13M15.12M
Income Before Tax(53.64M)(64.47M)(43.98M)(120.96M)(229.71M)
Pre-Tax Margin—————
Income Tax Expense4.76K36.37K94.39K282.2K611K
Net Income(53.64M)(49.97M)(36.01M)(118.94M)(227.32M)
Net Margin—————
EPS (Basic)(1.45)(2.20)(0.73)(1.89)(3.53)
EPS (Diluted)(1.45)(2.20)(0.73)(1.89)(3.53)
Weighted Avg Shares36.93M29.36M49.12M62.87M64.46M
Weighted Avg Shares (Diluted)36.93M29.36M49.12M62.87M64.46M

MoonLake Immunotherapeutics

NASDAQ:MLTX

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.